참고문헌
- N, Yamamoto S, Fukuda H, et al (2009). Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol, 10, 1063-9. https://doi.org/10.1016/S1470-2045(09)70259-1
- Cancer Information Service, National Cancer Center, Japan (2013). Cancer motality (1958-2013).xls. [Internet]. Available from: http://ganjoho.jp/professional/statistics.
- Cunningham D, Starling N, Rao S, et al (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358, 36-46. https://doi.org/10.1056/NEJMoa073149
- Ford HE, Marshall A, Bridgewater JA, et al (2014). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol, 15, 78-86. https://doi.org/10.1016/S1470-2045(13)70549-7
- Glimelius B, Ekstrom K, Hoffman K, et al (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8, 163-8. https://doi.org/10.1023/A:1008243606668
- Hosokawa A, Sugiyama T, Ohtsu A, et al (2007). Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy. J Gastroenterol, 42, 533-8. https://doi.org/10.1007/s00535-007-2059-3
- Inal A, Kaplan MA, Kucukoner M, et al (2012). Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study. Asian Pac J Cancer Prev, 13, 3869-72. https://doi.org/10.7314/APJCP.2012.13.8.3869
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Kadowaki S, Komori A, Narita Y, et al (2014). Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment. Int J Clin Oncol, 19, 656-61. https://doi.org/10.1007/s10147-013-0610-1
- Kang JH, Lee SI, Lim do H, et al (2012). Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol, 30, 1513-8. https://doi.org/10.1200/JCO.2011.39.4585
- Koizumi W, Narahara H, Hara T, et al (2008). S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol, 9, 215-21. https://doi.org/10.1016/S1470-2045(08)70035-4
- Koo DH, Ryoo BY, Kim HJ, et al (2011). A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. Cancer Chemother Pharmacol, 68, 913-21. https://doi.org/10.1007/s00280-011-1561-8
- Lee J, Lim T, Uhm JE, et al (2007a). Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol, 18, 886-91. https://doi.org/10.1093/annonc/mdl501
- Lee SS, Lee JL, Ryu MH, et al (2007c). Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol, 37, 30-7.
- Park IH, Kim SY, Kim YW, et al (2011). Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement. Cancer Chemother Pharmacol, 67, 127-36. https://doi.org/10.1007/s00280-010-1296-y
- Pyrhonen S, Kuitunen T, Nyandoto P, et al (1995). Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 71, 587-91. https://doi.org/10.1038/bjc.1995.114
- Saitoh H, Boku N, Ohtsu A, et al (2000). Five-year survivor with liver metastasis from gastric cancer successfully treated with systemic chemotherapy. Gastric Cancer, 3, 106-9. https://doi.org/10.1007/PL00011694
- Schildberg CW, Weidinger T, Hohenberger W, et al (2014). Metastatic adenocarcinomas of the stomach or esophagogastric junction (UICC stage IV) are not always a palliative situation: a retrospective analysis. World J Surg, 38, 419-25. https://doi.org/10.1007/s00268-013-2293-1
- Takahari D, Boku N, Mizusawa J, et al (2014). Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. Oncologist, 19, 358-66. https://doi.org/10.1634/theoncologist.2013-0306
- Tetzlaff ED, Faust J, Ajani JA (2006). Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. Gastric Cancer, 9, 140-3. https://doi.org/10.1007/s10120-006-0363-x
- Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
- Thuss-Patience PC, Kretzschmar A, Bichev D, et al (2011). Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer, 47, 2306-14. https://doi.org/10.1016/j.ejca.2011.06.002
- Van Cutsem E, Moiseyenko VM, Tjulandin S, et al (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7. https://doi.org/10.1200/JCO.2006.06.8429
- Yamamoto M, Matsuyama A, Yoshinaga K, et al (2012). Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination. Oncol Lett, 3, 662-6.
- Yoshida M, Ohtsu A, Boku N, et al (2004). Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol, 34, 654-9. https://doi.org/10.1093/jjco/hyh120
피인용 문헌
- Factors Affecting Long Term Survival for Metastatic Gastric Cancer Treated with Chemotherapy vol.16, pp.2, 2016, https://doi.org/10.7704/kjhugr.2016.16.2.97
- Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety vol.16, pp.3, 2017, https://doi.org/10.1080/14740338.2017.1273348